Raymond Barlow begins tenure as e-Therapeutics CEO

Drug discovery company e-Therapeutics confirmed on Thursday that Raymond Barlow had assumed his position as chief executive officer.

The AIM-traded firm initially announced his appointment on 9 January.

Dr Barlow was previously executive director of corporate development at Amgen, based in Switzerland.

The company’s board said he was bringing experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector.

His previous responsibilities also included scientific, business and corporate roles with AstraZeneca, Crucell NV and Johnson and Johnson.

“e-Therapeutics is at the forefront of a new wave of science and has created a unique, computational-based drug discovery platform,” Dr Barlow said.

“This platform uses a range of truly cutting-edge technologies, including artificial intelligence.”

He said he was “convinced” of the value in the platform and the company’s differentiated approach to drug discovery, which could allow it and potential partners to more efficiently discover more effective drug treatments.

“My near-term aim is to ensure that our resources are appropriately focused on activities that are of the greatest commercial potential to support our ambition of creating value for our shareholders.

“As part of this process, I am looking forward to engaging with our key stakeholders as well as subsequently positioning and promoting the company to an industry which needs the assets and solutions we can provide.”